183 related articles for article (PubMed ID: 19139128)
1. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.
Afshar S; Asai T; Morrison SL
Mol Cancer Ther; 2009 Jan; 8(1):185-93. PubMed ID: 19139128
[TBL] [Abstract][Full Text] [Related]
2. Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine.
Afshar S; Sawaya MR; Morrison SL
Protein Sci; 2009 May; 18(5):1107-14. PubMed ID: 19388075
[TBL] [Abstract][Full Text] [Related]
3. Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.
Afshar S; Olafsen T; Wu AM; Morrison SL
J Exp Clin Cancer Res; 2009 Dec; 28(1):147. PubMed ID: 19958550
[TBL] [Abstract][Full Text] [Related]
4. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.
Bennett EM; Anand R; Allan PW; Hassan AE; Hong JS; Levasseur DN; McPherson DT; Parker WB; Secrist JA; Sorscher EJ; Townes TM; Waud WR; Ealick SE
Chem Biol; 2003 Dec; 10(12):1173-81. PubMed ID: 14700625
[TBL] [Abstract][Full Text] [Related]
5. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
6. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
7. 6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.
Hassan AEA; Abou-Elkhair RAI; Parker WB; Allan PW; Secrist JA
Eur J Med Chem; 2016 Jan; 108():616-622. PubMed ID: 26724729
[TBL] [Abstract][Full Text] [Related]
8. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
9. Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside.
Deharvengt S; Wack S; Uhring M; Aprahamian M; Hajri A
Pancreas; 2004 Mar; 28(2):E54-64. PubMed ID: 15028961
[TBL] [Abstract][Full Text] [Related]
10. Design of an adenosine phosphorylase by active-site modification of murine purine nucleoside phosphorylase. Enzyme kinetics and molecular dynamics simulation of Asn-243 and Lys-244 substitutions of purine nucleoside phosphorylase.
Maynes JT; Yam W; Jenuth JP; Gang Yuan R; Litster SA; Phipps BM; Snyder FF
Biochem J; 1999 Dec; 344 Pt 2(Pt 2):585-92. PubMed ID: 10567244
[TBL] [Abstract][Full Text] [Related]
11. Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors.
Daddona PE; Wiesmann WP; Milhouse W; Chern JW; Townsend LB; Hershfield MS; Webster HK
J Biol Chem; 1986 Sep; 261(25):11667-73. PubMed ID: 3091593
[TBL] [Abstract][Full Text] [Related]
12. Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.
Parker WB; Allan PW; Ealick SE; Sorscher EJ; Hassan AE; Silamkoti AV; Fowler AT; Waud WR; Secrist JA
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):387-92. PubMed ID: 16247956
[TBL] [Abstract][Full Text] [Related]
13. PNP anticancer gene therapy.
Zhang Y; Parker WB; Sorscher EJ; Ealick SE
Curr Top Med Chem; 2005; 5(13):1259-74. PubMed ID: 16305530
[TBL] [Abstract][Full Text] [Related]
14. Trypanosoma cruzi adenine nucleoside phosphorylase. Purification and substrate specificity.
Miller RL; Sabourin CL; Krenitsky TA
Biochem Pharmacol; 1987 Feb; 36(4):553-60. PubMed ID: 3103626
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase.
Secrist JA; Parker WB; Allan PW; Bennett LL; Waud WR; Truss JW; Fowler AT; Montgomery JA; Ealick SE; Wells AH; Gillespie GY; Gadi VK; Sorscher EJ
Nucleosides Nucleotides; 1999; 18(4-5):745-57. PubMed ID: 10432677
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
Deharvengt S; Wack S; Aprahamian M; Hajri A
J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
[TBL] [Abstract][Full Text] [Related]
18. Computer Simulations Reveal Substrate Specificity of Glycosidic Bond Cleavage in Native and Mutant Human Purine Nucleoside Phosphorylase.
Isaksen GV; Hopmann KH; Åqvist J; Brandsdal BO
Biochemistry; 2016 Apr; 55(14):2153-62. PubMed ID: 26985580
[TBL] [Abstract][Full Text] [Related]
19. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
20. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
Heinis C; Alessi P; Neri D
Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
